annual EBITDA:
-$51.38M-$17.58M(-52.00%)Summary
- As of today (September 16, 2025), TRVI annual EBITDA is -$51.38 million, with the most recent change of -$17.58 million (-52.00%) on December 31, 2024.
- During the last 3 years, TRVI annual EBITDA has fallen by -$18.95 million (-58.44%).
- TRVI annual EBITDA is now -524.04% below its all-time high of -$8.23 million, reached on December 31, 2017.
Performance
TRVI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$13.68M-$2.25M(-19.69%)Summary
- As of today (September 16, 2025), TRVI quarterly EBITDA is -$13.68 million, with the most recent change of -$2.25 million (-19.69%) on June 30, 2025.
- Over the past year, TRVI quarterly EBITDA has dropped by -$433.00 thousand (-3.27%).
- TRVI quarterly EBITDA is now -516.12% below its all-time high of -$2.22 million, reached on December 1, 2017.
Performance
TRVI quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$51.37M-$433.00K(-0.85%)Summary
- As of today (September 16, 2025), TRVI TTM EBITDA is -$51.37 million, with the most recent change of -$433.00 thousand (-0.85%) on June 30, 2025.
- Over the past year, TRVI TTM EBITDA has dropped by -$8.34 million (-19.39%).
- TRVI TTM EBITDA is now -2213.06% below its all-time high of -$2.22 million, reached on December 1, 2017.
Performance
TRVI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRVI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -52.0% | -3.3% | -19.4% |
| 3 y3 years | -58.4% | -75.2% | -71.1% |
| 5 y5 years | -93.1% | -84.9% | -68.8% |
TRVI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -71.8% | at low | -106.0% | +2.6% | -72.0% | +0.0% |
| 5 y | 5-year | -93.1% | at low | -106.0% | +2.6% | -72.0% | +0.0% |
| alltime | all time | -524.0% | at low | -516.1% | +2.6% | -2213.1% | +0.0% |
TRVI EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$13.68M(+19.7%) | -$51.37M(+0.9%) |
| Mar 2025 | - | -$11.43M(-6.3%) | -$50.94M(-0.9%) |
| Dec 2024 | -$51.38M(+52.0%) | -$12.21M(-13.1%) | -$51.38M(+6.9%) |
| Sep 2024 | - | -$14.05M(+6.0%) | -$48.07M(+11.7%) |
| Jun 2024 | - | -$13.25M(+11.6%) | -$43.03M(+12.9%) |
| Mar 2024 | - | -$11.87M(+33.4%) | -$38.13M(+12.8%) |
| Dec 2023 | -$33.80M(+13.0%) | -$8.90M(-1.2%) | -$33.80M(+7.2%) |
| Sep 2023 | - | -$9.01M(+7.9%) | -$31.54M(+2.0%) |
| Jun 2023 | - | -$8.35M(+10.7%) | -$30.93M(+1.8%) |
| Mar 2023 | - | -$7.54M(+13.6%) | -$30.39M(+1.8%) |
| Dec 2022 | -$29.90M(-7.8%) | -$6.64M(-20.9%) | -$29.86M(-5.1%) |
| Sep 2022 | - | -$8.40M(+7.5%) | -$31.48M(+4.9%) |
| Jun 2022 | - | -$7.81M(+11.4%) | -$30.02M(-4.3%) |
| Mar 2022 | - | -$7.01M(-15.1%) | -$31.36M(-3.3%) |
| Dec 2021 | -$32.43M | -$8.26M(+19.1%) | -$32.43M(-2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$6.93M(-24.3%) | -$33.34M(-0.9%) |
| Jun 2021 | - | -$9.15M(+13.4%) | -$33.64M(+5.5%) |
| Mar 2021 | - | -$8.08M(-12.0%) | -$31.89M(-1.7%) |
| Dec 2020 | -$32.44M(+21.9%) | -$9.18M(+27.0%) | -$32.44M(+8.1%) |
| Sep 2020 | - | -$7.23M(-2.3%) | -$30.02M(-1.3%) |
| Jun 2020 | - | -$7.40M(-14.2%) | -$30.43M(-0.0%) |
| Mar 2020 | - | -$8.63M(+27.7%) | -$30.43M(+14.4%) |
| Dec 2019 | -$26.61M(+44.7%) | -$6.76M(-11.5%) | -$26.61M(+3.3%) |
| Sep 2019 | - | -$7.64M(+3.1%) | -$25.77M(+42.1%) |
| Jun 2019 | - | -$7.41M(+54.2%) | -$18.13M(+20.1%) |
| Mar 2019 | - | -$4.80M(-18.8%) | -$15.10M(+46.7%) |
| Dec 2018 | -$18.39M(+123.3%) | -$5.92M(+35.2%) | -$10.29M(+56.0%) |
| Jun 2018 | - | -$4.38M(+97.0%) | -$6.60M(+197.0%) |
| Dec 2017 | -$8.23M(-4.5%) | - | - |
| Dec 2017 | - | -$2.22M | -$2.22M |
| Dec 2016 | -$8.62M | - | - |
FAQ
- What is Trevi Therapeutics, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Trevi Therapeutics, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Trevi Therapeutics, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Trevi Therapeutics, Inc.?
- What is Trevi Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Trevi Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of TRVI is -$51.38M
What is the all time high annual EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high annual EBITDA is -$8.23M
What is Trevi Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, TRVI annual EBITDA has changed by -$17.58M (-52.00%)
What is Trevi Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of TRVI is -$13.68M
What is the all time high quarterly EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high quarterly EBITDA is -$2.22M
What is Trevi Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, TRVI quarterly EBITDA has changed by -$433.00K (-3.27%)
What is Trevi Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of TRVI is -$51.37M
What is the all time high TTM EBITDA for Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. all-time high TTM EBITDA is -$2.22M
What is Trevi Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, TRVI TTM EBITDA has changed by -$8.34M (-19.39%)